Premium
Vitamin D Metabolites as Clinical Markers in Autoimmune and Chronic Disease
Author(s) -
Blaney Greg P.,
Albert Paul J.,
Proal Amy D.
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.04875.x
Subject(s) - vitamin d and neurology , calcitriol receptor , vitamin d deficiency , medicine , autoimmune disease , endocrinology , osteoporosis , psoriasis , immunology , disease
Recent research has implicated vitamin D deficiency (serum levels of 25‐hydroxyvitamin D <50 nmol/L) with a number of chronic conditions, including autoimmune conditions such as multiple sclerosis, lupus, and psoriasis, and chronic conditions such as osteoporosis, osteoarthritis, metabolic syndrome, fibromyalgia and chronic fatigue syndrome. It has been assumed that low levels of 25‐hydroxyvitamin D (25‐D) accurately indicate vitamin D storage and vitamin D receptor (VDR)–mediated control of calcium metabolism and innate immunity. To evaluate this assumption, 25‐D and 1,25‐dihydroxyvitamin D3 (1,25‐D) levels were measured in 100 Canadian patients with these conditions. Additionally, other inflammatory markers (CK, CRP) were measured. Results showed a strong positive association between these autoimmune conditions and levels of 1,25‐D >110 pmol/L. However, there was little association with vitamin D deficiency or the other inflammatory markers, meaning that the results challenge the assumption that serum levels of 25‐D are a sensitive measure of the autoimmune disease state. Rather, these findings support the use of 1,25‐D as a clinical marker in autoimmune conditions. High levels of 1,25‐D may result when dysregulation of the VDR by bacterial ligands prevents the receptor from expressing enzymes necessary to keep 1,25‐D in a normal range.